Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03658434

Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer — PRADO  

Hormone-refractory Prostate Cancer Clinical Trial

Official title:
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer

Clinical Trial Summary

The aim of the present feasibility study of a new short palliative radiotherapy regime that apply to patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominating debilitating symptom. Diffusion weighted magnetic resonance imaging (DWI) will apply to identify both the lesion and the most aggressive part of the lesion. The symptomatic lesions will be treated with a dose of 4 x 5 Gy, while for the most aggressive part of the lesion the dose will be escalated to 4 x 7 Gy using a simultaneous integrated boost (SIB) technique.

Clinical Trial Description

Please refer to uploaded Study Protocol ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03658434
Study type Interventional
Source Zealand University Hospital
Contact Redas Trepiakas, MD
Phone +45 56 51 3231
Email rtr@regionsjaelland.dk
Status Recruiting
Phase N/A
Start date August 1, 2018
Completion date August 1, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03076203 - Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) Phase 1
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Completed NCT00201357 - An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer Phase 2
Completed NCT00337077 - Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Phase 2
Completed NCT00675545 - A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients Phase 2
Completed NCT01133704 - Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT03016741 - Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Phase 4
Completed NCT00570700 - Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer Phase 2
Completed NCT02288936 - Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer Phase 2
Completed NCT00636740 - Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Completed NCT01422850 - Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy Phase 1
Recruiting NCT05997615 - Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT00891345 - Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy Phase 1
Completed NCT00151073 - Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate Phase 2
Terminated NCT00048659 - YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Phase 2
Completed NCT00082134 - Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel Phase 2